BIOLIFE SOLUTIONS INC (BLFS) Stock Overview
USA - NASDAQ:BLFS - US09062W2044 - Common Stock
BLFS Key Statistics, Chart & Performance
The current stock price of BLFS is 28.66 USD. In the past month the price increased by 18.53%. In the past year, price increased by 30.1%.
BLFS Latest News, Press Relases and Analysis
BLFS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.53 | 215.96B | ||
| DHR | DANAHER CORP | 28.89 | 159.49B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 147.87 | 48.23B | ||
| A | AGILENT TECHNOLOGIES INC | 27.06 | 41.80B | ||
| IQV | IQVIA HOLDINGS INC | 19.17 | 37.38B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.15 | 29.62B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 43.46 | 22.09B | ||
| WAT | WATERS CORP | 29.08 | 21.17B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.72 | 16.76B | ||
| ILMN | ILLUMINA INC | 24.03 | 15.37B | ||
| TEM | TEMPUS AI INC | N/A | 15.12B | ||
| ICLR | ICON PLC | 13.65 | 14.00B |
Related stock screener links
About BLFS
Company Profile
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 159 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Company Info
BIOLIFE SOLUTIONS INC
Suite 310, 3303 Monte Villa Parkway
Bothell WASHINGTON 98021 US
CEO: Michael Rice
Employees: 159
Phone: 14254011400
BIOLIFE SOLUTIONS INC / BLFS FAQ
What does BIOLIFE SOLUTIONS INC do?
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 159 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
What is the current price of BLFS stock?
The current stock price of BLFS is 28.66 USD. The price increased by 4.07% in the last trading session.
What is the dividend status of BIOLIFE SOLUTIONS INC?
BLFS does not pay a dividend.
How is the ChartMill rating for BIOLIFE SOLUTIONS INC?
BLFS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for BIOLIFE SOLUTIONS INC?
BIOLIFE SOLUTIONS INC (BLFS) operates in the Health Care sector and the Life Sciences Tools & Services industry.
Can you provide the growth outlook for BIOLIFE SOLUTIONS INC?
The Revenue of BIOLIFE SOLUTIONS INC (BLFS) is expected to decline by -5.07% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
BLFS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BLFS. When comparing the yearly performance of all stocks, BLFS is one of the better performing stocks in the market, outperforming 86.15% of all stocks.
BLFS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BLFS. No worries on liquidiy or solvency for BLFS as it has an excellent financial health rating, but there are worries on the profitability.
BLFS Financial Highlights
Over the last trailing twelve months BLFS reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 115.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.43% | ||
| ROE | -1.59% | ||
| Debt/Equity | 0 |
BLFS Forecast & Estimates
16 analysts have analysed BLFS and the average price target is 31.93 USD. This implies a price increase of 11.4% is expected in the next year compared to the current price of 28.66.
For the next year, analysts expect an EPS growth of 28.86% and a revenue growth -5.07% for BLFS